Generic Name |
Cixutumumab | |
---|---|---|
IND |
IMC-A12 | |
Brand Name (US) |
||
Manufacturer |
ImClone | |
Drug Type |
monoclonal antibody | |
Delivery |
Intravenous | |
Approval Status |
Phase 2 | |
Indications |
||
Overall Strategy |
GIST cell based | |
Strategy |
Block related tumor signal paths | |
Drug Category |
IGF1R inhibitor |
This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.